Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial
Authors:
- Zhe ChenZCZhe Chen
- Bai LiBLBai Li
- Feng ShenFSFeng Shen
- Jia FanJFJia Fan
- Wei-Ping ZhouWZWei-Ping Zhou
- Yun-Ke YangYYYun-Ke Yang
- Jing XuJXJing Xu
- Xiao QinXQXiao Qin
- Le-Qun LiLLLe-Qun Li
- Chang-Quan LingCLChang-Quan Ling
- 1 March 2013
- journal article
- research article
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 11 (2) , 90-100
Abstract
Disease recurrence is a main challenge in treatment of hepatocellular carcinoma (HCC). There is no generally accepted method for preventing recurrence of HCC after resection. To compare the efficacy of a traditional herbal medicine (THM) regimen and transarterial chemoembolization (TACE) in preventing recurrence in post-resection patients with small HCC. This is a multicenter, open-label, randomized, controlled study, which was undertaken in five centers of China. A total of 379 patients who met the eligibility criteria and underwent randomization were enrolled in this trial. One hundred and eighty-eight patients were assigned to the THM group and received Cinobufacini injection and Jiedu Granule, and the other 191 patients were assigned to the TACE group and received one single course of TACE. Primary outcome measures were the annual recurrence rate and the time to recurrence. Incidence of adverse events was regarded as the secondary outcome measure. Among the 364 patients who were included in the intention-to-treat analysis, 67 patients of the THM group and 87 of the TACE group had recurrence, with a hazard ratio of 0.695 (P = 0.048). Median recurrence-free survival of the patients in the THM and TACE groups was 46.89 and 34.49 months, respectively. Recurrence rates at 1, 2 and 3 years were 17.7%, 33.0% and 43.5% for the THM group, and 28.8%, 42.5% and 54.0% for the TACE group, respectively (P = 0.026). Multivariate analysis indicated that the THM regimen had a big advantage for prolonging the recurrence-free survival. Adverse events were mild and abnormality of laboratory indices of the two groups were similar. In comparison with TACE therapy, the THM regimen was associated with diminished risk of recurrence of small-sized HCC after resection, with comparable adverse events. TRIAL REGISTRTION IDENTIFIER: This trial was registered in the Chinese Clinical Trial Registry with the identifier ChiCTR-TRC-07000033.Keywords
This publication has 25 references indexed in Scilit:
- Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinomaCochrane Database of Systematic Reviews, 2009
- A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular CarcinomaAnnals of Surgery, 2007
- Management of Hepatocellular Carcinoma *Hepatology, 2005
- Use of complementary and alternative medicine in cancer patients: a European surveyAnnals of Oncology, 2005
- Liver Resection for Hepatocellular Carcinoma on CirrhosisAnnals of Surgery, 2003
- Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomyJournal of Hepatology, 2003
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trialsThe Lancet Oncology, 2002
- Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver FunctionAnnals of Surgery, 2002
- Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trialThe Lancet, 2000